GlassScriptPhysician profile
Andrew Lebson
NPI 1043755952
$4,412.29
in general payments reported to CMS, 2019-2025
37 companies · $757 in 2025
The $757 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $594 · 2022: $863 · 2023: $1,217 · 2024: $981 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,954.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $787.88 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $609.73 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $342.00 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $304.88 | 2021-2025 | |
| Radius Health, INC. | $279.02 | 2021-2025 | Tymlos |
| Amgen INC. | $198.83 | 2021-2025 | Prolia, Evenity, Tepezza |
| Corcept Therapeutics | $197.05 | 2022-2025 | Korlym |
| Abbott Laboratories | $141.67 | 2021-2024 | Freestyle Libre 3 |
| Medtronic, INC. | $137.80 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Insulet Corporation | $122.30 | 2021-2025 | Omnipod |
| Cequr Corporation | $114.91 | 2023-2024 | Cequr Simplicity |
| Ibsa Pharma INC. | $107.00 | 2021-2024 | Tirosint, Tirosint, Licart |
| Amneal Pharmaceuticals LLC | $105.32 | 2023-2025 | Unithroid |
| Astrazeneca Pharmaceuticals LP | $80.29 | 2022-2025 | Lokelma, Farxiga |
| Antares Pharma, INC. | $79.15 | 2022-2024 | Xyosted, Nocdurna, Tlando |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $73.90 | 2023-2024 | |
| Embecta Corp. | $55.68 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Merck Sharp & Dohme LLC | $54.71 | 2021-2022 | |
| Dexcom, INC. | $49.04 | 2023-2025 | Dexcom G6 Transmitter |
| Clarus Therapeutics INC. | $45.67 | 2021 | |
| Lifescan, INC. | $43.66 | 2021-2022 | |
| Amarin Pharma, INC. | $43.23 | 2021-2022 | |
| Mannkind Corporation | $42.13 | 2021-2023 | Afrezza |
| Xeris Pharmaceuticals, INC. | $41.43 | 2023-2024 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $39.87 | 2025 | |
| Horizon Therapeutics Plc | $37.11 | 2021-2022 | |
| Beta Bionics, INC. | $35.04 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Alexion Pharmaceuticals, INC. | $35.02 | 2023 | Strensiq |
| Tandem Diabetes Care, INC. | $32.28 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.47 | 2025 | Jardiance |
| Sequel Med Tech, LLC | $25.16 | 2025 | Twiist |
| Becton, Dickinson and Company | $24.48 | 2022 | |
| Kyowa Kirin, INC. | $23.87 | 2023 | Crysvita |
| Ipsen Biopharmaceuticals, INC | $22.46 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.66 | 2025 | |
| Glaxosmithkline, LLC. | $17.97 | 2025 | Arexvy, Shingrix |
| Recordati_rare_diseases_inc. | $15.62 | 2025 | Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Lebson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.